

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 8

**Complete if Known**

Application Number	10/600,266
Filing Date	June 20, 2003
First Named Inventor	Fumitoshi Asai
Art Unit	1629
Examiner Name	Leslie A. Royds
Attorney Docket Number	17620-105003

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		GB 2469883	11-03-2010	Sandoz AG		
		WO 09/130289	10-29-2009	Sandoz AG		

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Algaier et al., "Interaction of the Active Metabolite of Prasugrel, R-138727, with Cysteine 97 and Cysteine 175 of the Human P2Y <sub>12</sub> Receptor," Journal of Thrombosis and Haemostasis, 6, pp. 1908-1914, 2008	
		Allender et al., European Cardiovascular Disease Statistics, 2008 Edition, pp. 1-112	
		Angiolillo et al., "Increased Platelet Inhibition After Switching From Maintenance Clopidogrel to Prasugrel in Patients with Acute Coronary Syndromes," Journal of the American College of Cardiology, 56(13), pp. 1017-1023, 2010	
		Armstrong et al., "In the Presence of Strong P2Y <sub>12</sub> Receptor Blockade, Aspirin Provides Little Additional Inhibition of Platelet Aggregation," Journal of Thrombosis and Haemostasis, 9, pp. 552-561, 2011	
		Asai et al., "A Comparison of Prasugrel (CS-747, LY640315) With Clopidogrel on Platelet Function in Healthy Male Volunteers," Oral Contributions - Features Oral Session...Platelet Resistance: Importance, Detection, and Treatment, Abstract No. 868-B, March 9, 2005, JACC, Abstracts - Angiography & Interventional Cardiology, pp. 86A - 90A, February 1, 2005	
		Asai et al., "CS-747, a New Platelet ADP Receptor Antagonist," Annu. Rep. Sankyo Res. Lab., 54, pp. 1-44, 1999	
		Becker et al., "Synthesis, SAR and In Vivo Activity of Novel Thienopyridine Sulfonamide Pyrrolidinones as Factor Xa Inhibitors," Bioorganic & Medicinal Chemistry Letters, 9, pp. 2753-2758, 1999	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 8

**Complete if Known**

Application Number	10/600,266
Filing Date	June 20, 2003
First Named Inventor	Fumitoshi Asai
Art Unit	1629
Examiner Name	Leslie A. Royds
Attorney Docket Number	17620-105003

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Bertilsson, "Geographical/Interracial Differences in Polymorphic Drug Oxidation: Current State of Knowledge of Cytochromes P450 (CYP) 2D6 and 2C19," Clinical Pharmacokinetics, 29(3), pp. 192-209, September 1995, Abstract only	
		Bhatt et al., "Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events," The New England Journal of Medicine, 354(16), pp. 1706-1717, April 20, 2006	
		CAPRIE Steering Committee, "A Randomised, Blinded, Trial of Clopidogrel Versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE)," The Lancet, 348, pp. 1329-1339, November 16, 1996	
		COMMIT, "Addition of Clopidogrel to Aspirin in 45852 Patients With Acute Myocardial Infarction: Randomised Placebo-Controlled Trial," www.thelancet.com, 366, pp. 1607-1621, 2005	
		Corr et al., "Managing Heart Disease Coronary Revascularization: Knife or Catheter?," European Heart Journal Supplements, pp. B43-B48, 2003	
		Cosma et al., "Relationship Between Genotype and Function of the Human CYP1A1 Gene," Journal of Toxicology and Environmental Health, part A, vol. 4, pp. 309-316, October 1993 (Abstract Only)	
		Crofts et al., "Function Significance of Different Human CYP1A1 Genotypes," Oxford Journals Carcinogenesis, Abstract, 1994	
		Declaration of Dr. Joseph A. Jakubowski filed in the European Opposition Proceedings for EP 1 350 511, January 1, 2011	
		Declaration of Dr. Robert William Gristwood filed in the European Opposition Proceedings for EP 1 350 511, January 19, 2011	
		Declaration of Dr. Ian Boden Wilkinson filed in the European Opposition Proceedings for EP 1 350 511, January 20, 2011	
		Dovlatova et al., "The Reversible P2Y <sub>12</sub> Antagonist Cangrelor Influences the Ability of the Active Metabolites of Clopidogrel and Prasugrel to Produce Irreversible Inhibition of Platelet Function," Journal of Thrombosis and Haemostasis, 6, pp. 1153-1159, 2008	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 3 of 8

**Complete if Known**

Application Number	10/600,266
Filing Date	June 20, 2003
First Named Inventor	Fumitoshi Asai
Art Unit	1629
Examiner Name	Leslie A. Royds
Attorney Docket Number	17620-105003

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Eisenstein et al., "Clopidogrel Use and Long Term Clinical Outcomes After Drug-Eluting Stent Implantation," JAMA, 297(2), pp. 159-168, 2007	
		EMA, "Assessment Report for Efient®," European Medicines Agency, Evaluation of Medicines for Human Use, EMA/117561/2009	
		Erlinge et al., "Patients with Poor Responsiveness to Thienopyridine Treatment and those With Diabetes Have Lower Levels of Circulating Active Metabolite, but their Platelets Respond Normally to Active Metabolite," 2008 Congress of the European Society of Cardiology, Abstract P3573, August 30, 2008	
		Fox et al., "The ENACT Study: a pan-European Survey of Acute Coronary Syndromes," European Heart Journal, 21, pp.1440-1449, 2000	
		Frelinger III, et al., "The Active Metabolite of Prasugrel Inhibits Adenosine Diphosphate-and Collagen-Stimulated Platelet Procoagulant Activities," J. of Thrombosis and Haemostasis, 6, pp. 359-365, 2007	
		Frelinger III, et al., "Abstract 3293: The Active Metabolite of Prasugrel Inhibits Platelet Procoagulant Activities," Circulation, 114, p. 699, 2006, Abstract Only	
		Frelinger III, et al., "The Active Metabolite of Prasugrel Inhibits ADP-Stimulated Thrombo-Inflammatory Markers of Platelet Activation: Influence of Other Blood Cells, Calcium, and Aspirin," Thrombosis Haemostasis, 98, pp. 192-200, 2007	
		Geiger et al., "Specific Impairment of Human Platelet P2Y <sub>12</sub> ADP Receptor - Mediated Signaling by the Antiplatelet Drug Clopidogrel," Arterioscler Thromb Vasc Biol., pp. 2007-2011, August 1999	
		Giusti, "Response to Antiplatelet Treatment: From Genes to Outcome," www.thelancet.com, pp. 1-3, 2010	
		Gryglewski et al., "Thrombolysis by Thienopyridines and Their Congeners," Journal of Physiology and Pharmacology, 51(4), pp. 683-693, 2000	
		Harker et al., "Mechanism of Action of Dipyridamole," Thrombosis Research, pp. 39-46, 1983	
		Hasegawa et al., "Stereoselective Inhibition of Human Platelet Aggregation by R-138727, the Active Metabolite of CS-747 (Prasugrel, LY640315), a Novel P2Y <sub>12</sub> Receptor Inhibitor," Thromb. Haemost., 94, pp. 593-598, 2005	

Examiner  
SignatureDate  
Considered

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>2</sup> Applicant's unique citation designation number (optional). <sup>3</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 4 of 8

**Complete if Known**

Application Number	10/600,266
Filing Date	June 20, 2003
First Named Inventor	Fumitoshi Asai
Art Unit	1629
Examiner Name	Leslie A. Royds
Attorney Docket Number	17620-105003

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Hashimoto et al., "The Influence of P2Y <sub>12</sub> Receptor Deficiency on the Platelet Inhibitory Activities of Prasugrel in a Mouse Model: Evidence for Specific Inhibition of P2Y <sub>12</sub> Receptors by Prasugrel," Biochemical Pharmacology, 74, pp. 1003-1009, 2007	
		Hirota et al., "Efficacy of CS-747, A New Potent Antiplatelet Agent," Clinical Pharmacology & Therapeutics, 65(2), p. 148, February 1999	
		Holmes et al., "ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDS "Boxed Warning," Circulation, 122, pp. 537-557, 2010	
		Ingall et al., "Antagonists of the Platelet P <sub>2T</sub> Receptor: A Novel Approach to Antithrombotic Therapy," J. Med. Chem., 42, pp. 213-220, 1999	
		Judge et al., "The Active Metabolite of Prasugrel Effectively Blocks the Platelet P2Y <sub>12</sub> Receptor and Inhibits Procoagulant and pro-inflammatory Platelet Responses," Platelets, 19(2), pp. 125-133, March 2008	
		Judge et al., "Relationship between Degree of P2Y <sub>12</sub> Receptor Blockade and Inhibition of P2Y <sub>12</sub> -Mediated Platelet Function," Thrombosis and Haemostasis, 103, pp. 1-8, 2010	
		Kamishirado et al., "Randomized Comparison of Cilostazol Versus Ticlopidine Hydrochloride for Antiplatelet Therapy After Coronary Stent Implantation for Prevention of Late Restenosis," Am. Heart J., 144(2), pp. 303-308, 2002	
		Karlberg et al., "Comparison of Three Independent Methods as Estimates of Platelet Inhibition After a Single Dose of Acetylsalicylic Acid," Scand J. Clin. Lab. Invest., 53, pp. 835-841, 1993	
		Kazui et al., "Mechanism for Production of Pharmacologically Active Metabolite of CS-747, A New Anti-Platelet Agent," Pharmacokinetics, vol. 16, pp. S78-S79, 2001	
		L'Allier et al., "Clopidogrel 600-Mg Double Loading Dose Achieves Stronger Platelet Inhibition Than Conventional Regimens," Journal of the American College of Cardiology, 51(11), pp. 1066-1072, 2008	
		Lepantalo, "Individual Variation in <i>In Vitro</i> Efficacy of Antiplatelet Medication," Coagulation Disorders Unit, Division of Hematology, Department of Medicine, Helsinki University Central Hospital, Finland and Department of Medicine, Institute of Clinical Medicine, Faculty of Medicine, University of Helsinki, Finland, 2007	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 5 of 8

**Complete if Known**

Application Number	10/600,266
Filing Date	June 20, 2003
First Named Inventor	Fumitoshi Asai
Art Unit	1629
Examiner Name	Leslie A. Royds
Attorney Docket Number	17620-105003

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Lopez-Farre et al., "Effects of Aspirin on Platelet-Neutrophil Interactions," Circulation, 91, pp. 2080-2088, 1995	
		Mega et al., "Genetic Variants in ABCB1 and CYP2C19 and Cardiovascular Outcomes after Treatment with Clopidogrel and Prasugrel in the TRITON-TIMI 38 Trial: a Pharmacogenetic Analysis," <a href="http://www.thelancet.com">www.thelancet.com</a> , pp. 1-8, 2010	
		Montalescot et al., "Prasugrel Compared with High-Dose Clopidogrel in Acute Coronary Syndrome," Thrombosis and Haemostasis, pp. 213-223, 2010	
		Montalescot et al., "Prasugrel Compared with Clopidogrel in Patients undergoing Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction (TRITON-TIMI 38): Double-Blind, Randomised Controlled Trial," <a href="http://www.thelancet.com">www.thelancet.com</a> , 373, pp. 723-731, February 28, 2009	
		Niitsu et al., "Prasugrel (CS-747, LY640135) Hydrochloride, a Novel Thienopyridine Prodrug, Shows Potent Antiplatelet and Antithrombotic Effects with Rapid Onset of Action in Rats," Blood, 106, Abstract. 1879, p. 534A, 2005	
		Niitsu et al., "Repeat Oral Dosing of Prasugrel, a Novel P2Y <sub>12</sub> Receptor Inhibitor, Results in Cumulative and Potent Antiplatelet and Antithrombotic Activity in Several Animal Species," European Journal of Pharmacology, 579, pp. 276-282, 2008	
		Ogawa et al., "Effects of Prasugrel, a Novel P2Y <sub>12</sub> Inhibitor, in Rat Models of Cerebral and Peripheral Artery Occlusive Disease," European Journal of Pharmacology, 612, pp. 29-34, 2009	
		Peters et al., "Effects of Aspirin Dose When Used Alone or In Combination with Clopidogrel in Patients with Acute Coronary Syndrome: Observations From the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) Study," Circulation, pp. 1682-1687, 2003	
		Prescribing Information - Effient, 2009	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 6 of 8

**Complete if Known**

Application Number	10/600,266
Filing Date	June 20, 2003
First Named Inventor	Fumitoshi Asai
Art Unit	1629
Examiner Name	Leslie A. Royds
Attorney Docket Number	17620-105003

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Puma et al., "Thrombolytic, Antithrombin, and Antiplatelet Treatment of Acute Coronary Syndromes," J. Am. Osteopath Assoc., 100(1), pp. S8-12, 2000	
		Ratiopharm Submission for EP 1 350 511 filed January 21, 2011	
		Rauch et al., "Regulation of Functionally Active P2Y <sub>12</sub> ADP Receptors by Thrombin in Human Smooth Muscle Cells and the Presence of P2Y <sub>12</sub> in Carotid Artery Lesions," Arterioscler Thromb. Vasc. Biol., 30, pp. 2434-2442, 2010	
		Rauch et al., "Thrombin upregulated expression of functionally active P2Y <sub>12</sub> ADP receptors in human vascular smooth muscle cells," 50 <sup>th</sup> Annual Meeting, Deutsche Gesellschaft für Experimentelle und Klinische Pharmakologie und Toxikologie, Mainz, March 10-12, 2009, Naunyn-Schmiedeberg's Arch Pharmacol., 379 (suppl. 1), pp. 1-100, 2009	
		Reist et al., "Very Slow Chiral Inversion of Clopidogrel in Rats: A Pharmacokinetic and Mechanistic Investigation," Drug Metabolism and Disposition, 28(12), pp. 1405-1410, 2000	
		Roden et al., "Responding to the Clopidogrel Warning by the US Food and Drug Administration, Real Life is Complicated," Circulation, 122, pp. 445-448, 2010	
		Rothwell et al., "Effect of Daily Aspirin on Long-Term Risk of Death Due to Cancer: Analysis of Individual Patient Data from Randomised Trials," www.TheLancet.com, pp. 1-11, 2010	
		Sabatine et al., "Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with ST-Segment Elevation," The New England Journal of Medicine, 352(12), pp. 1179-1189 March 24, 2005	
		Savi et al., "The Antiaggregating Activity of Clopidogrel is Due to a Metabolic Activation by the Hepatic Cytochrome P450-1A," Thrombosis and Haemostasis, 72(2), pp. 313-317, 1994	
		Schrör et al., "Prasugrel, ein neues Thienopyridin," Homöostaseologie, pp. 351-355, 2007	
		Schwarz et al., "Flow Cytometry Analysis of Intracellular VASP Phosphorylation for the Assessment of Activating and Inhibitory Signal Transduction Pathways in Human Platelets," Thromb. Haemost., 82, pp. 1145-1152, 1999	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 7 of 8

**Complete if Known**

Application Number	10/600,266
Filing Date	June 20, 2003
First Named Inventor	Fumitoshi Asai
Art Unit	1629
Examiner Name	Leslie A. Royds
Attorney Docket Number	17620-105003

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Serebruany, "Lack of Outcome Benefit and Clopidogrel "resistance" - The Triton Trial Challenge," Thrombosis and Haemostasis, pp. 415-418, 2010	
		Smith et al., "Abstract 10881: Mortality Benefit with Prasugrel in TRITON-TIMI 38 Coronary Artery Bypass Grafting (CABG) Cohort: Risk Adjusted Retrospective Data Analysis," Circulation, 122, A10881, 2010	
		Spinler et al., "Review of Prasugrel for the Secondary Prevention of Atherothrombosis," J. Manag. Care Pharm., 15(5), pp. 383-395, 2009	
		Steinhuibl et al., "Attainment and Maintenance of Platelet Inhibition Through Standard Dosing of Abciximab in Diabetic and Nondiabetic Patients Undergoing Percutaneous Coronary Intervention," Circulation, pp. 1977-1982, November 9, 1999	
		Steinhuibl et al., "Early and Sustained Dual Oral Antiplatelet Therapy Following Percutaneous Coronary Intervention," JAMA, 288(19), pp. 2411-2420, corrections on p. 987, November 20, 2002	
		Storey et al., "The Central Role of the P <sub>2T</sub> Receptor in Amplification of Human Platelet Activation, Aggregation, Secretion and Procoagulant Activity," British Journal of Haematology, 110, pp. 925-934, 2000	
		Sugidachi et al., "Anti-Platelet and Anti-Thrombotic Effects of CS-747, a Novel P <sub>2Y</sub> <sub>12</sub> Receptor Antagonist, In Combination With Aspirin," NIA- Exhibition Area, Supplement to the Journal of Thrombosis and Haemostasis, Abstract P2032, July 2003	
		Sugidachi et al., Antiplatelet Action of R-99224, An Active Metabolite of a Novel Thienopyridine-Type G <sub>1</sub> -Linked P <sub>2T</sub> Antagonist, CS-747," British Journal of Pharmacology, 132, pp. 47-54, 2001	
		Sugidachi et al., "The Greater in vivo Antiplatelet Effects of Prasugrel as Compared to Clopidogrel Reflect More Efficient Generation of its Active Metabolite with Similar Antiplatelet Activity to that of Clopidogrel's Active Metabolite," Journal of Thrombosis and Haemostasis, 5, pp. 1545-1551, 2007	
		Sugitachi et al., "Pharmacological Action of Prasugrel: Novel Platelet P <sub>2Y</sub> <sub>12</sub> Receptor Inhibitor," Cell, 39(14), pp. 30(607) - 33(610), 2007 (with certified English translation)	
		Togni et al., "Percutaneous Coronary Interventions in Europe 1992-2001," European Heart Journal, 25, pp. 1208-1213, 2004	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 8 of 8

**Complete if Known**

Application Number	10/600,266
Filing Date	June 20, 2003
First Named Inventor	Fumitoshi Asai
Art Unit	1629
Examiner Name	Leslie A. Royds
Attorney Docket Number	17620-105003

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Vane et al., "Cycooxygenases 1 and 2," Annu. Rev. Pharmacol. Toxicol., 38, pp. 97-120, 1998	
		Varenhorst et al., "Abstract 3201: Greater P2Y12 Inhibition with Prasugrel Compared With Clopidogrel in Aspirin-Treated Patients Based on Higher Plasma Concentration of the Active Metabolite," Circulation, 116, pp. 719-720, 2007, Abstract Only	
		Weber et al., "Specific Inhibition of ADP-Induced Platelet Aggregation by Clopidogrel in vitro," British Journal of Pharmacology, 126, pp. 415-210, 1999	
		Wiviott et al., "Prasugrel," Circulation, 122, pp. 394-403, 2010	
		Written Submission filed by Daiichi Sankyo for EP 1 350 511 dated December 24, 2010	
		Written Submission for EP 1 350 511 dated January 20, 2011	
		Written Submission for EP 1 350 511 dated February 18, 2011	
		Ziemianin et al., "Thienopyridines: Effects on Cultured Endothelial Cells," Journal of Physiology and Pharmacology, 50(4), pp. 597-604, 1999	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.